Acne in adult women – impact on quality of life
Acne is often viewed as a disease of adolescence but for many women it persists into adulthood. In a qualitative study of 50 adult women with acne, participants… read more.
Acne is often viewed as a disease of adolescence but for many women it persists into adulthood. In a qualitative study of 50 adult women with acne, participants… read more.
Eli Lilly and Company and Incyte announced that the FDA will not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental new drug application… read more.
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicines Agency will update the Dupixent (dupilumab) summary of product characteristics (SmPC) adding long-term safety results for adults with… read more.
Scientists isolated a molecule, extracted from the leaves of the European chestnut tree, with the power to neutralize dangerous, drug-resistant staph bacteria. Frontiers in Pharmacology published the finding, led by… read more.
LEO Pharma announced that the European Commission (EC) has approved Adtralza (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy…. read more.
Mallinckrodt Plc announced that the FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the treatment of adults with thermal burns… read more.
Novartis,has announced the FDA has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for… read more.
Organon celebrates its launch as a global women’s health company with employees and women from around the world, as the Organon executive leadership team rings the opening bell… read more.
Almirall S.A. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the regulatory approval… read more.
Merck Inc., hosted on 3 May an Organon management investor day meeting, to detail across women’s health, biosimilars and established brands.The new company will be launched on 3… read more.
Amgen announced Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease , according… read more.
AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic… read more.